GlassScriptPhysician profile
Bharathi Gopalakrishna
NPI 1336528033
$5,878.61
in general payments reported to CMS, 2019-2025
34 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $1,379 · 2023: $1,311 · 2024: $1,560 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,122.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,199.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $839.49 | 2021-2025 | |
| Lilly USA, LLC | $535.82 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $507.34 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $406.01 | 2022-2025 | |
| Glaxosmithkline, LLC. | $339.57 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $284.65 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $239.56 | 2022-2025 | Rexulti |
| Dexcom, INC. | $147.20 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $137.70 | 2022 | |
| Esperion Therapeutics, INC. | $132.21 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $117.03 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.08 | 2022-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.92 | 2022-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $87.66 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.49 | 2021-2023 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $73.35 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $68.54 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $62.64 | 2022-2025 | Veozah |
| Idorsia Pharmaceuticals US INC | $58.05 | 2023 | Quviviq |
| Pfizer INC. | $51.89 | 2022-2023 | |
| Verity Pharmaceuticals INC. | $42.99 | 2024-2025 | Tlando |
| Almatica Pharma LLC | $31.91 | 2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $29.83 | 2022 | |
| Merck Sharp & Dohme LLC | $23.34 | 2022 | |
| Nestle Healthcare Nutrition INC. | $23.21 | 2022 | |
| Exact Sciences Corporation | $23.19 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $22.90 | 2022 | |
| Hologic Sales and Service, LLC | $22.68 | 2024 | Aptima, Thinprep 2000 Processor |
| Philips North America LLC | $17.49 | 2023 | |
| Amneal Pharmaceuticals LLC | $17.13 | 2024 | Unithroid |
| Azurity Pharmaceuticals, INC. | $14.02 | 2025 | Azmiro |
| Ibsa Pharma INC. | $13.43 | 2022 | |
| Genentech USA, INC. | $9.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bharathi Gopalakrishna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.